Kratom compound MG001 enters first human safety trial
NCT ID NCT07204171
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is the first time MG001, a formulation of mitragynine from the kratom plant, is being tested in people. Researchers want to see if it is safe and how the body processes it. About 32 healthy adults who have used oral opioids recently will receive a single dose of MG001 or a placebo and be monitored closely for several days. This early-phase trial focuses only on safety, not on treating any condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MG001 (mitragynine, a compound from the kratom plant)
- What this could lead to
- If successful, this could pave the way for larger studies exploring MG001 as a potential treatment for opioid withdrawal symptoms.
- What could go wrong
- This is a very early Phase 1 safety study with only 32 people. It is not designed to test effectiveness, and the results may not lead to any approved treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY AND TOLERABILITY IN HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Altasciences Clinical Kansas
Overland Park, Kansas, 66212, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.